Anastrozole aromatase inhibitors

Description Results NMA

Clinical benefit (assessable) 1.06 [0.91; 1.24]

Objective response (assessable) 1.16 [0.87; 1.55]

vomiting 0.91 [0.64; 1.30]

diarrhoea 1.32 [0.87; 2.01]

nausea 0.97 [0.77; 1.22]

progression-free survival (reported or calculated) 1.34 [0.79; 2.28]

Objective response (randomised) 1.16 [0.87; 1.55]

Clinical benefit (randomised) 1.06 [0.91; 1.24]

thromboembolic 1.13 [0.57; 2.24]

rash 1.33 [0.80; 2.22]

hot flushes 0.98 [0.75; 1.27]

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

thromboembolic 0.55 [0.31; 0.97]

Clinical benefit (assessable) 0.91 [0.81; 1.02]

Objective response (assessable) 0.93 [0.77; 1.14]

vomiting 1.07 [0.69; 1.65]

diarrhoea 1.22 [0.79; 1.91]

overall survival (reported or calculated) 0.97 [0.53; 1.77]

nausea 0.90 [0.70; 1.15]

progression-free survival (reported or calculated) 0.82 [0.48; 1.40]

Objective response (randomised) 0.93 [0.77; 1.14]

Clinical benefit (randomised) 0.91 [0.81; 1.02]

vaginal bleeding 0.46 [0.16; 1.31]

hot flushes 1.15 [0.93; 1.42]

Clinical benefit (assessable) 0.67 [0.56; 0.81]

Clinical benefit (randomised) 0.67 [0.56; 0.81]

Objective response (assessable) 0.75 [0.51; 1.10]

overall survival (reported or calculated) 0.92 [0.43; 1.98]

Objective response (randomised) 0.75 [0.51; 1.10]

anastrozole 1 mg once daily (n=340)

vs.

tamoxifen 20 mg once daily (n=328)

Parallel groups

Sample size: 340/328

Primary endpoint: TTP

FU duration:

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

diarrhoea 3.17 [1.39; 7.26]

Clinical benefit (assessable) 0.96 [0.78; 1.17]

Objective response (assessable) 0.98 [0.62; 1.55]

vomiting 1.53 [0.86; 2.74]

overall survival (reported or calculated) 0.78 [0.39; 1.57]

nausea 1.39 [0.91; 2.11]

Objective response (randomised) 0.98 [0.62; 1.55]

Clinical benefit (randomised) 0.96 [0.78; 1.17]

thromboembolic 0.72 [0.31; 1.69]

vaginal bleeding 0.48 [0.20; 1.18]

rash 0.74 [0.39; 1.38]

hot flushes 1.56 [0.93; 2.62]

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration: